UBS Initiates Coverage On Nurix Therapeutics With Buy Rating, Announces Price Target of $35
UBS Initiates Coverage On Nurix Therapeutics With Buy Rating, Announces Price Target of $35
瑞银开始对nurix therapeutics进行买入评级，宣布目标股价为35美元
UBS analyst David Dai initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Buy rating and announces Price Target of $35.
瑞银分析师大卫·戴开始对nurix therapeutics (纳斯达克：NRIX) 进行买入评级，并宣布目标股价为35美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。